APA (7th ed.) Citation

Mei, J., Jiang, G., Chen, Y., Xu, Y., Wan, Y., Chen, R., . . . Xu, J. (2022). HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. BMC Cancer, 22(1), 1. https://doi.org/10.1186/s12885-022-09840-6

Chicago Style (17th ed.) Citation

Mei, Jie, et al. "HLA Class II Molecule HLA-DRA Identifies Immuno-hot Tumors and Predicts the Therapeutic Response to Anti-PD-1 Immunotherapy in NSCLC." BMC Cancer 22, no. 1 (2022): 1. https://doi.org/10.1186/s12885-022-09840-6.

MLA (9th ed.) Citation

Mei, Jie, et al. "HLA Class II Molecule HLA-DRA Identifies Immuno-hot Tumors and Predicts the Therapeutic Response to Anti-PD-1 Immunotherapy in NSCLC." BMC Cancer, vol. 22, no. 1, 2022, p. 1, https://doi.org/10.1186/s12885-022-09840-6.